On the stock market since 2014, it operates in the world of health and science. It has 860 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 134% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 3 years, sales grew about 103% a year on average.
The company sells $680.9M a year; the problem isn’t sales — it’s costs running above that number.
There is $1.0B in the vault; even if every debt were paid off, $984.1M would remain.
A loss of $74.7M against $680.9M in annual sales.
The stock trades 25% above the average analyst price target.
On our five-subject report card, ITCI sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: ITCI has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.